Smith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty
Smith+Nephew ((LSE: SN, NYSE:SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation CORI◊ XT Handheld Robotics Platform, marking an important milestone in the clinical introduction of its latest handheld robotics technology.
CORI XT Handheld Robotic Platform is designed to be the single handheld robotics platform for all orthopaedic needs - partial to revision knee, hip*, and anatomic and reverse shoulders - with a footprint tailored to the unique needs of hospitals and ambulatory surgical suites settings. These early cases represent the first use of CORI XT Platform across both knee and shoulder arthroplasty and reflect Smith+Nephew's Skill Amplified approach to handheld robotics—designing technology to support and enhance surgeon expertise while preserving surgeon control, clinical judgment, and efficient workflows.
First robotic shoulder arthroplasty cases globally in hospital and ASC settings
The first shoulder arthroplasty cases using CORI XT Platform were performed at Duke Health by a surgical team led by Dr. Christopher Klifto. Dr. Klifto utilized CORI◊ SHOULDER Handheld Robotic Arthroplasty in combination with the AETOS◊ Shoulder System. CORI SHOULDER offers a complete robotic procedure, supporting handheld robotic execution of the humerus and glenoid, across both anatomic and reverse procedures.
Dr. Klifto said, "The CORI SHOULDER workflow was streamlined and efficient; registration and planning were seamless; and the post‑op x‑rays matched our pre‑op planning. A proud moment for the team and an exciting milestone for shoulder robotics."
Building on this initial clinical experience, Dr. Bertrand Kaper completed the first CORI XT shoulder arthroplasty cases in an ambulatory surgery center (ASC) setting at North Valley Surgery Center in Scottsdale, Arizona, further expanding the use of CORI XT Platform across care environments, and highlighting the versatility and fit of the CORI XT Platform in an ASC setting, and the well-suited nature of handheld robotics to shoulder arthroplasty.
Reflecting on these first cases, Dr. Kaper said, "It is a privilege to be part of this transformative effort to bring the accuracy of robotic technology to the surgical treatment of shoulder arthritis. The use of CORI Handheld Robotics allows us to merge advanced technology with surgical expertise to deliver personalized care for shoulder surgery. As we have witnessed with our knee replacement patients, robotic technology enhances the potential for patient recovery and implant longevity. I am confident that these innovations will become the standard for helping our patients who are dealing with the pain and disability of shoulder arthritis."
To learn more, please visit our CORI SHOULDER website.
First knee replacement cases with CORI XT Platform at NYU Langone
The first knee replacement procedures performed using the CORI XT Handheld Robotics Platform were completed at NYU Langone Health by Dr. Ran Schwarzkopf, orthopedic surgeon and joint replacement specialist. These cases mark the first clinical use of CORI XT Platform in knee arthroplasty and an important milestone in the platform's broader rollout as its applications continue to expand.
Handheld robotics designed for accuracy1 without compromising efficiency
CORI XT Platform is designed to provide the benefits of robotic assistance while preserving the efficiency and familiarity of established surgical workflows. Its handheld form factor enables surgeons to access robotic guidance and execution support without disrupting procedural flow or adding operational complexity to the operating room.
As part of Smith+Nephew's Skill Amplified robotics approach, CORI XT Platform is designed to enhance accuracy1 while maintaining surgeon control, tactile feedback, and decision‑making throughout the procedure. By integrating naturally into how surgeons already operate, the platform supports consistent execution without requiring changes to operating room setup or procedural workflow.
With its compact footprint and mobility, CORI XT Platform is suited for use across both hospital and ambulatory surgery center environments.2 The system integrates with Smith+Nephew's CORIOGRAPH◊ Pre-Operative Planning and Modeling Services to support patient‑specific planning while enabling efficient intraoperative execution.
"These first clinical cases reflect close collaboration with surgeon partners and our commitment to introducing handheld robotics in a thoughtful and practical way," said Mayank Shandil, Smith+Nephew Senior Vice President, Global Marketing Orthopaedics and Robotics. "Our Skill Amplified approach focuses on supporting surgical accuracy while enabling surgeons to work efficiently and confidently within their preferred workflows."
The CORI XT Platform is part of Smith+Nephew's broader MTECH (Musculoskeletal Technologies to Enhance Care and Healing) portfolio, spanning robotics, navigation, visualization, and enabling technologies across orthopaedic surgery.
- ends –
*CORI HIP Handheld Robotic Arthroplasty indication is under development
References:
1. Bollars P, Janssen D, De Weerdt W, et al. Improved accuracy of implant placement with an imageless handheld robotic system compared to conventional instrumentation in patients undergoing total knee arthroplasty: a prospective randomized controlled trial using CT-based assessment of radiological outcomes. Knee Surg Sports Traumatol Arthrosc. 2023;31(12):5446-5452.
2. Smith+Nephew 2020. Internal report. ER0488 Rev. B Smith+Nephew 2020. Comparison of operating room footprint for robotic-assisted knee arthroplasty systems. Internal Report. EO.REC.PCS015.002.v1.
Media Enquiries
Gina Kamler +1 (901) 262-9070
Smith+Nephew gina.kamler@smith-nephew.com
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $6.2 billion in 2025. Smith+Nephew is a constituent of the FTSE100 ((LSE:SN, NYSE:SNN). The terms ‘Group' and ‘Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
